*Doctors measure disability progression using a test called the Expanded Disability Status Scale, or EDSS. Your first score—or your “baseline”—will determine how your disability is gauged moving forward. If your baseline score is ≤5.5, you’re considered to have sustained disability progression if that score goes up by 1 point (lasting at least 12 weeks). If your baseline score is >5.5, you’re considered to have sustained disability progression if that score goes up by at least 0.5 point (lasting at least 12 weeks).
†14 mg only.
AUBAGIO (teriflunomide) 14 mg was shown to be effective vs. placebo in 3 key measures: relapses, disability progression, and brain lesions. AUBAGIO 7 mg was shown to be effective vs. placebo in 2 of the 3 key measures—relapses and brain lesions.
‡The clinical trials were each given a name. Trial 1 was called TEMSO; Trial 2 was called TOWER; and Trial 3 was called TOPIC.
If you are concerned about relapses, ask your healthcare provider if once-daily AUBAGIO may be right for you.
on AUBAGIO 14 mg vs. 46% with placebo.
54% remained relapse-free on AUBAGIO 7 mg vs. 46% with placebo.
31% reduction in relapse rate with both AUBAGIO
14 mg and 7 mg vs. placebo.
on AUBAGIO 14 mg vs. 47% with placebo.
58% remained relapse-free on AUBAGIO 7 mg vs. 47% with placebo.
36% reduction in relapse rate with AUBAGIO 14 mg and 22% reduction with 7 mg vs. placebo.
on AUBAGIO 14 mg vs. 62% with placebo.
71% remained relapse-free on AUBAGIO 7 mg vs. 62% with placebo.
on AUBAGIO 14 mg and 7 mg vs. placebo.
on AUBAGIO 14 mg vs. placebo.
22% reduction in relapse rate on AUBAGIO 7 mg vs. placebo.
This extension study followed participants who stayed on AUBAGIO 5.5 years after the original study ended.
Disability progression was looked at in 2 of the clinical trials. In both of those trials, AUBAGIO 14 mg was shown to help keep more people free from disability progression.
AUBAGIO 7 mg did not achieve a statistically significant reduction in risk of sustained disability progression.
with AUBAGIO 14 mg vs. 73% with placebo.
78% remained free of disability progression with AUBAGIO 7 mg vs. 73% with placebo.
with AUBAGIO 14 mg vs. 80% with placebo.
79% remained free of disability progression with AUBAGIO 7 mg vs. 80% with placebo.
If you’re concerned about disability progression, take a look at this study. The results may be meaningful to you. The study found that the majority of participants showed no disability progression for up to 7.5 years—the treatment was AUBAGIO.
Think about what you were doing 2 years ago, and what you can do today. Is your current treatment meeting your needs? Visit Exploring Treatment to learn more.
Patients taking AUBAGIO had a reduced risk of new brain lesions vs. placebo.
with AUBAGIO 14 mg vs. placebo.
57% fewer new lesions with AUBAGIO 7 mg vs. placebo.
§AUBAGIO is effective against MRI lesion activity.
∥Average contrast-enhancing lesions per scan.
AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Are of childbearing potential and not using effective birth control.
It is not known if AUBAGIO passes into breast milk. Your healthcare provider can help you decide if you should take AUBAGIO or breastfeed — you should not do both at the same time.
If you are a man whose partner plans to become pregnant, you should stop taking AUBAGIO and talk with your healthcare provider about reducing the levels of AUBAGIO in your blood. If your partner does not plan to become pregnant, use effective birth control while taking AUBAGIO.
AUBAGIO may stay in your blood for up to 2 years after you stop taking it. Your healthcare provider can prescribe a medicine that can remove AUBAGIO from your blood quickly.
Before taking AUBAGIO, talk with your healthcare provider if you have: liver or kidney problems; a fever or infection, or if you are unable to fight infections; numbness or tingling in your hands or feet that is different from your MS symptoms; diabetes; serious skin problems when taking other medicines; breathing problems; or high blood pressure. Your healthcare provider will check your blood cell count and TB test before you start AUBAGIO. Talk with your healthcare provider if you take or are planning to take other medicines (especially medicines for treating cancer or controlling your immune system), vitamins or herbal supplements.
AUBAGIO may cause serious side effects, including: reduced white blood cell count — this may cause you to have more infections; numbness or tingling in your hands or feet that is different from your MS symptoms; allergic reactions, including serious skin problems; breathing problems (new or worsening); and high blood pressure. Patients with low white blood cell count should not receive certain vaccinations during AUBAGIO treatment and 6 months after.
Tell your doctor if you have any side effect that bothers you or does not go away.
The most common side effects when taking AUBAGIO include: headache; diarrhea; nausea; hair thinning or loss; and abnormal liver test results. These are not all the side effects of AUBAGIO. Tell your healthcare provider about any side effect that bothers you.
Consult your healthcare provider if you have questions about your health or any medications you may be taking, including AUBAGIO.
IMPORTANT SAFETY INFORMATION
Do not take AUBAGIO if you have severe liver problems. AUBAGIO may cause serious liver problems, which can be life-threatening. Your risk may be higher if you take other medicines that affect your liver. View More